International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. - Wikidata - wikimedia - TriplyDB

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

http://www.wikidata.org/entity/Q37507513

about

Pomalidomide for the treatment of multiple myeloma International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Recent advances in multiple myeloma: a Korean perspective Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.Bortezomib in multiple myeloma: systematic review and clinical considerations.Immunomodulatory drugs in multiple myeloma.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma.Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.A Case of Posterior Mediastinal Plasmacytoma Confounded by Community-Acquired Pneumonia Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries Challenges in multiple myeloma diagnosis and treatment.How best to use new therapies in multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?Perspectives in the treatment of multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.Incorporating novel agents in the management of elderly myeloma patients.Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.Staging and prognostication of multiple myeloma Reconstruction of multiple myeloma lesions around the pelvis and acetabulum.Treatment-related symptom management in patients with multiple myeloma: a review.The serological diagnostic challenges of multiple myeloma.Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation Novel Induction Regimens in Multiple Myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Age-related health care disparities in multiple myeloma.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.

P2860

Q26859133-5EA46CCE-BC62-4900-B9B9-70F661880170 Q27002668-A618000A-863E-4C40-BC79-627837DBE4A2 Q28074521-C5962808-AAF8-4A75-AA0F-7FD2C7B80F5D Q30962747-E8B41905-2D4B-4987-9894-5BD9C7D23CBF Q33429115-0BC381B5-272C-4031-B061-9FC232E4B4FF Q33982728-D2BEEA98-F1DB-434A-BA69-63ECAD3D62B1 Q34325722-8BE3F4E6-4AD4-4F5A-9A01-6C62E44174AF Q34539519-250C1BEC-BBD0-49F2-B45E-04CB4F3B45C8 Q35104606-454197CC-FBDD-4A10-A079-34670AC33D8E Q35263009-7CC5B35D-1A42-4465-A4D4-F63E35932AF6 Q35298727-ADC1B149-5A34-42D9-91B8-43266E700DF4 Q35410550-1738D9B4-9C39-4A76-BC18-BEF9146F6C23 Q35843835-7200DB33-F779-4EDD-A1D7-1009A64484B1 Q36503079-8BF8A2EE-3550-45F2-A845-5BA943AD2248 Q36536365-01D071D6-5F74-4AD1-86B6-17DB923EC780 Q36611288-FE7AF887-DE0A-4E80-8675-D2ABF2BC044A Q36852225-E163C228-7596-479E-9A9C-7716B4EB6549 Q37723000-9F170987-3010-4342-A1C0-D0A53A04B08E Q37761370-12250D43-494E-40AF-B522-3B613910BE9C Q37851944-00F28F31-03B6-4F2F-B2E3-F8022717AA46 Q37858523-4CBA6723-2D20-4F55-90B5-12E9BB3D700E Q38000078-C98544B6-7E9B-438E-B1DA-BE1A5B2FEF9B Q38037600-C6F32D36-0176-4E0A-A4EB-D1334B81134B Q38096055-61EA7E9C-8479-49F2-89BD-1D49CC47C05E Q38098877-595AECD0-DA8C-4A76-94F6-ABB28866241B Q38108391-0E2DC778-E6C0-4978-A481-7ECA32FD6FB7 Q38139989-1A142EBF-6B76-46FE-B2CB-B56E2B6B4128 Q38146974-91D40D75-9CAA-45DC-95AE-0CDCEDE5D518 Q38154927-77D060F1-9C7E-4585-8470-80A91C831964 Q38183871-6E624DA8-A78C-40F5-B59D-1803C354EF89 Q38261214-10804A3B-9A4B-446D-8B03-5BCC94AF76D2 Q38342281-B957496C-5D10-464B-B69A-E1798B8BBB2D Q38351789-E8E07512-25CF-4D91-84CF-B9DC0EC2F496 Q38385471-CF7F324F-C244-4AB1-AB52-8D71C98DCCD4 Q38496485-7CB20827-B48F-4754-BED9-B605B01CEE55 Q38567017-4F0E3203-8224-43FC-8CCB-E45EDB6BCCA1 Q38630472-71484065-8C56-4D96-BC8C-2E2E1105005A Q38692424-4FA4916D-9F84-47AD-8C99-279168748FBA Q38833538-C7BE40E5-FF8A-47D0-99D4-C2DDC7977271 Q39007207-4FB0ABB3-6B90-4DBE-BDA0-29FE099852E6

P2860

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

http://www.wikidata.org/entity/Q37507513

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

International Myeloma Working ...... ous stem cell transplantation.

@en

International Myeloma Working ...... ous stem cell transplantation.

@nl

type

label

International Myeloma Working ...... ous stem cell transplantation.

@en

International Myeloma Working ...... ous stem cell transplantation.

@nl

prefLabel

International Myeloma Working ...... ous stem cell transplantation.

@en

International Myeloma Working ...... ous stem cell transplantation.

@nl

P1433

Q37507513-BDDE9CD8-45E8-4D0B-B06C-84EAAED39CC3

P1476

Q37507513-DB9A2CA4-0F26-47C3-8540-CFAFD81545C5

P2093

Q37507513-0F3C5727-3008-4D09-8A47-37DCC6CAC6CF

Q37507513-163F1881-76D4-4B47-80D5-B86A961F5B9E

Q37507513-16EEFFF4-1380-454D-9757-626CE6AC14CB

Q37507513-19EBBE95-A76E-435A-8338-83A89513C080

Q37507513-260EB9E4-5C19-42F4-B9E3-1DC8512F49D9

Q37507513-2B03AE72-3F82-4C77-A1DB-748F004DB4C2

Q37507513-2FA773B0-D679-40FA-8E2A-EBF5BFE8F16B

Q37507513-3C6BA68A-41ED-44EC-B0DD-B0EC67FEFB7D

Q37507513-49C911FD-72F0-44AA-B757-3E540A7D7AF9

Q37507513-627F24FF-47AA-4E9D-9373-3B521A10124F

P2860

Q37507513-04C7E02A-B37F-4C82-9205-E969E7BC35DB

Q37507513-05E3623A-4341-467F-B66A-DE4C7577B581

Q37507513-07CFC384-0C9C-4B62-8528-3684FB320435

Q37507513-1B24D918-9889-4D16-A54D-337E2F41DA3D

Q37507513-1DD704DA-D0EF-4950-AB01-C64B34899F43

Q37507513-1FD0676F-4467-466F-8351-CA03A9D677FC

Q37507513-204FC141-5A0E-4EDF-AF0F-DE214F2166CC

Q37507513-216EAA12-27B6-40FE-A4ED-34C12FE5546F

Q37507513-291B29F9-FFC2-42F0-AFF0-8BC3A26DF498

Q37507513-2C6B266A-10CF-46DB-8CF9-70907BEF6682

P2888

Q37507513-A128E5FC-AFDC-4B72-88ED-3E5F180D0971

P304

Q37507513-42F1CBCB-EDAB-44AC-B406-0002746DB99F

P31

Q37507513-D2D2613D-2D03-4705-BC69-44F162FB44C3

P356

Q37507513-ED441D14-F5A2-43D6-8200-3B350E9B6D64

P433

Q37507513-FC85C86F-2498-447A-BEE7-A3B0B482C88F

P478

Q37507513-E16968DC-25F4-430C-A9FC-8751041FD127

P50

Q37507513-62D5152D-245E-488D-9331-58918151B6FE

Q37507513-827B54F1-9538-4EEB-A8BA-B44EC2064ED1

Q37507513-EC9D8DFE-04E4-4500-A1AC-5C7965183D20

P577

Q37507513-A19C83DF-C0ED-413B-A882-D93368421A12

P5875

Q37507513-33388A70-4526-4208-9027-BED31003EEA8

P6179

Q37507513-0A4728BD-8CDD-4EB5-BB08-52E08CD2C8B7

P698

Q37507513-91B3EC7A-1ECD-4832-BED8-17A1DB025A36

P921

Q37507513-77328FFA-E1EB-4EB9-B749-3115542894C7

Q37507513-E843BFCA-AA1F-4F97-AF10-F84C5BEBB9C5

P356

P1433

P1476

International Myeloma Working ...... ous stem cell transplantation.

@en

P2093

A Palumbo

http://www.w3.org/2001/XMLSchema#string

A Spencer

http://www.w3.org/2001/XMLSchema#string

B G M Durie

http://www.w3.org/2001/XMLSchema#string

D Joshua

http://www.w3.org/2001/XMLSchema#string

F Davies

http://www.w3.org/2001/XMLSchema#string

G Morgan

http://www.w3.org/2001/XMLSchema#string

H Einsele

http://www.w3.org/2001/XMLSchema#string

H Ludwig

http://www.w3.org/2001/XMLSchema#string

I Turesson

http://www.w3.org/2001/XMLSchema#string

IMWG

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

Cancer statistics, 2008

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

P2888

P304

1716-1730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2009.122

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Meletios A. Dimopoulos

P577

2009-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26265236

http://www.w3.org/2001/XMLSchema#string

P6179

1007268714

http://www.w3.org/2001/XMLSchema#string

P698

19494840

http://www.w3.org/2001/XMLSchema#string

P921